VAXCYTE INC. - COMMON STOCK

Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies

16 Apr 2023 16:00:00 By Nasdaq GlobeNewswire

Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

30 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

27 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

21 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

16 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at the SVB Securities Global Biopharma Conference

07 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

05 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update

07 Nov 2022 15:10:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at Upcoming Investor Conferences

03 Nov 2022 07:30:01 By Nasdaq GlobeNewswire

Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

28 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Vaxcyte Announces Pricing of $600 Million Public Offering

25 Oct 2022 23:20:17 By Nasdaq GlobeNewswire

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

24 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

24 Oct 2022 05:30:00 By Nasdaq GlobeNewswire

Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults

23 Oct 2022 16:00:00 By Nasdaq GlobeNewswire

Vaxcyte Expands Executive Leadership Team with Key Appointments

11 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

06 Sep 2022 15:04:00 By Nasdaq GlobeNewswire

Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update

08 Aug 2022 15:15:00 By Nasdaq GlobeNewswire

Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

04 Aug 2022 07:30:01 By Nasdaq GlobeNewswire

Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults

12 Jul 2022 15:05:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at the Jefferies Healthcare Conference

02 Jun 2022 15:05:00 By Nasdaq GlobeNewswire